Semaglutide Boosts Walking Distance in Diabetic Peripheral Artery Disease Patients
Major trial shows weekly semaglutide injections significantly improved walking capacity in people with diabetes and leg artery disease.
Summary
The STRIDE trial tested whether semaglutide, a diabetes medication, could help people with peripheral artery disease walk farther. This condition affects over 230 million people globally, causing leg pain and reduced walking ability due to blocked arteries. Researchers studied 792 patients with both diabetes and symptomatic leg artery disease across 112 sites in 20 countries. After 52 weeks, patients receiving weekly semaglutide injections showed a 21% improvement in maximum walking distance compared to 8% in the placebo group—a statistically significant 13% greater improvement. The treatment was generally safe with minimal serious side effects.
Detailed Summary
Peripheral artery disease affects over 230 million people worldwide, causing debilitating leg pain and severely limiting walking ability due to blocked arteries in the legs. Few effective treatments exist to improve functional capacity and quality of life for these patients.
The STRIDE trial investigated whether semaglutide, a GLP-1 receptor agonist commonly used for diabetes, could improve walking capacity in patients with both type 2 diabetes and symptomatic peripheral artery disease. This phase 3b study enrolled 792 patients across 112 clinical sites in 20 countries, randomly assigning them to receive either weekly semaglutide 1.0 mg injections or placebo for 52 weeks.
The results were striking: patients receiving semaglutide achieved a median 21% improvement in maximum walking distance compared to just 8% in the placebo group. This represented a statistically significant 13% greater improvement with semaglutide treatment. The medication was generally well-tolerated, with similar rates of serious adverse events between groups and no treatment-related deaths.
These findings suggest semaglutide could offer new hope for millions suffering from peripheral artery disease, potentially improving their mobility and quality of life. The mechanism behind this benefit remains unclear and warrants further investigation. Future research should also explore whether these benefits extend to peripheral artery disease patients without diabetes, potentially expanding treatment options for this underserved population.
Key Findings
- Semaglutide increased maximum walking distance by 21% vs 8% with placebo
- Treatment effect showed 13% greater improvement compared to placebo group
- Study included 792 patients with diabetes and symptomatic peripheral artery disease
- Safety profile was favorable with no treatment-related deaths reported
- Results were statistically significant across 112 sites in 20 countries
Methodology
This was a phase 3b, double-blind, randomized, placebo-controlled trial conducted at 112 sites across 20 countries. Participants had type 2 diabetes and symptomatic peripheral artery disease with intermittent claudication, receiving either semaglutide 1.0 mg weekly or placebo for 52 weeks.
Study Limitations
The study only included patients with both diabetes and peripheral artery disease, limiting generalizability. The mechanism of benefit remains unclear, and long-term effects beyond 52 weeks are unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.